Table 2.

Cohorts included in the ATLANTIC clinical trial.

Cohort	EGFR/ALK status	PD-L1 expression	Number of patients
1	Mutated/positive	<25% or ⩾25%	111
2	Wild type/wild type	<25% or ⩾25%	265
3	Mutated/positive	⩾90%	68

ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; PD-L1, programmed death ligand 1.